In a patient with KDIGO stage 1 non‑oliguric acute kidney injury, should angiotensin‑receptor blockers and metformin be held, and what is the recommended management of starvation ketosis?

Management of ARBs and Metformin in KDIGO Stage 1 Non-Oliguric AKI

In KDIGO stage 1 non-oliguric AKI, temporarily discontinue both ARBs and metformin until kidney function stabilizes, then reassess for safe reinitiation based on eGFR recovery.

ARB Management in AKI

Temporarily hold ARBs during the acute phase of AKI, even in stage 1. The Canadian Society of Nephrology explicitly recommends temporary discontinuation of RAAS blockers (including ARBs) in patients with eGFR <60 mL/min/1.73 m² who have serious intercurrent illness that increases AKI risk 1. This "sick-day rule" applies to your KDIGO stage 1 patient, as AKI itself represents a serious intercurrent illness affecting kidney function.

Rationale for ARB Suspension

• ARBs reduce intraglomerular pressure by dilating efferent arterioles, which can worsen GFR during hemodynamic stress
• Even mild AKI (stage 1) represents a vulnerable state where autoregulation may be impaired
• The risk of worsening kidney injury outweighs short-term cardiovascular benefits during acute illness

When to Restart ARBs

Restart ARBs once kidney function stabilizes and returns toward baseline. High-quality evidence from parallel cohort studies in England and Sweden (7,303 and 1,790 patients respectively) demonstrates that continuing RAAS blockers after AKI does not increase risk of recurrent AKI or heart failure compared to stopping them 2. In fact, stopping ARBs was associated with increased mortality in the English cohort (HR 1.27,95% CI 1.15-1.41). This suggests that once the acute phase resolves, restarting ARBs is not only safe but potentially beneficial.

Key decision points for ARB reinitiation:

• Creatinine trending downward toward baseline
• Patient clinically stable without ongoing hemodynamic stress
• No persistent oliguria or volume depletion
• Underlying indication for ARB (heart failure, proteinuria, hypertension) still present

Metformin Management in AKI

Stop metformin immediately in any stage of AKI, regardless of oliguria status. The FDA drug label explicitly states metformin is contraindicated when eGFR falls below 30 mL/min/1.73 m² 3, and KDIGO 2022 guidelines recommend stopping metformin at eGFR <30 4. However, during acute kidney injury, even stage 1, the dynamic nature of kidney function and risk of further deterioration mandates suspension.

Critical Concerns with Metformin in AKI

The primary danger is metformin-associated lactic acidosis (MALA), which occurs when:

• Metformin accumulates due to reduced renal clearance (metformin is 90% renally excreted unchanged)
• Impaired lactate clearance by kidneys compounds the problem
• Mortality from MALA can exceed 50% in severe cases

The FDA label emphasizes that "postmarketing metformin-associated lactic acidosis cases primarily occurred in patients with significant renal impairment" 3. Even at recommended doses, case reports document severe AKI with lactic acidosis and metformin levels reaching 8.95 μg/mL (versus normal steady-state ~1 μg/mL) 5.

Specific Sick-Day Protocol

The Canadian guideline provides explicit "sick-day rules" recommending temporary discontinuation of metformin when AKI risk is elevated 1. Your patient with established KDIGO stage 1 AKI meets this criterion. The guideline suggests holding metformin during:

• Surgery or procedures with fasting
• Acute illness with dehydration risk
• Any condition causing hemodynamic instability
• Documented AKI of any stage

When to Restart Metformin

Restart metformin only after:

1. eGFR recovers to ≥30 mL/min/1.73 m² (absolute minimum per KDIGO) 4
2. Preferably wait until eGFR ≥45 mL/min/1.73 m² for full-dose reinitiation
3. Patient is clinically stable, eating/drinking normally
4. No ongoing risk factors for volume depletion or hemodynamic instability

Dosing upon reinitiation:

• If eGFR 30-44: Start at half the previous dose 4
• If eGFR 45-59: Consider dose reduction in certain conditions (elderly, heart failure, liver disease)
• If eGFR ≥60: Resume previous dose
• Monitor eGFR every 3-6 months when <60 4

Starvation Ketosis Management

Starvation ketosis in the context of AKI requires aggressive nutritional support and careful monitoring to prevent metabolic decompensation.

Immediate Assessment

Distinguish starvation ketosis from diabetic ketoacidosis (DKA):

• Starvation ketosis: Mild ketonemia/ketonuria, normal or mildly elevated glucose (<250 mg/dL), pH usually >7.30, mild anion gap
• DKA: Severe hyperglycemia (>250 mg/dL), pH <7.30, large anion gap, severe ketonemia

Management Strategy

For starvation ketosis with AKI:

1. Nutritional repletion is primary therapy:

   • Initiate carbohydrate intake (100-150g/day minimum) to suppress ketogenesis
   • KDIGO AKI guidelines suggest achieving 20-30 kcal/kg/day total energy intake 6
   • Provide 0.8-1.0 g/kg/day protein in non-catabolic AKI patients not on dialysis 6
   • Avoid protein restriction—this does NOT prevent or delay dialysis need 6

2. Fluid management:

   • Isotonic crystalloids (normal saline or lactated Ringer's) for volume repletion 6
   • Avoid colloids and starches in AKI patients 6
   • Monitor volume status carefully—both dehydration and overload worsen AKI

3. Monitor for refeeding syndrome:

   • Check phosphate, potassium, magnesium daily
   • Risk is higher with prolonged starvation (>5-7 days)
   • Supplement electrolytes proactively if deficient

4. Glycemic control:

   • Target glucose 110-149 mg/dL in critically ill patients 6
   • Use insulin if needed, but metformin remains contraindicated until AKI resolves
   • Avoid hypoglycemia, which worsens outcomes

Common Pitfalls to Avoid

With ARBs:

• Don't restart too early while creatinine still rising
• Don't permanently discontinue in patients with clear ongoing indications (proteinuric CKD, heart failure)
• Don't forget to reassess and restart—many patients never resume beneficial RAAS blockade after AKI

With metformin:

• Don't continue metformin "because eGFR is still >30"—the acute change matters more than absolute value
• Don't restart before confirming stable kidney function with repeat eGFR measurement
• Don't forget to counsel patients about sick-day rules for future illness

With starvation ketosis:

• Don't confuse with DKA and over-treat with insulin
• Don't restrict protein intake thinking it will protect kidneys
• Don't overlook electrolyte monitoring during nutritional repletion